572 PYX-102, an anti-KLRG1 antibody, enhances cytotoxic activity of CD8-T-cells from PBMC and human tumor samples by blocking the interaction between KLRG1 and cadherins

• Ronald Herbst,
• Anthony Rodriguez,
• Kei Yasuda,
• Philipp Steiner,
• Liyang Diao,
• Jianwen Feng,
• Matthew Iovino,
• Sara Lewandowski,
• Dan Felitsky,
• Ben Keller,
• Ona Miller,
• Alyssa Quigley,
• Jan Pinkas

Affiliations

Ronald Herbst

Aff162 grid.418152.bMedimmune Gaithersburg MD USA

Anthony Rodriguez

Aff573 grid.27755.32000000009136933XUniversity of Virginia Charlottesville VA USA

Kei Yasuda

1Renal Section

Philipp Steiner

Werewolf Therapeutics, Cambridge, MA, United States

Liyang Diao

Pyxis Oncology, Boston, MA, USA

Jianwen Feng

Pyxis Oncology, Boston, MA, USA

Matthew Iovino

Pyxis Oncology, Boston, MA, USA

Sara Lewandowski

Pyxis Oncology, Boston, MA, USA

Dan Felitsky

Pyxis Oncology, Boston, MA, USA

Ben Keller

Pyxis Oncology, Boston, MA, USA

Ona Miller

Pyxis Oncology, Boston, MA, USA

Alyssa Quigley

Pyxis Oncology, Boston, MA, USA

Jan Pinkas

Pyxis Oncology, Boston, MA, USA